Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Talquetamab by Johnson & Johnson for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Talquetamab is under clinical development by Johnson & Johnson and currently in Phase II for Multiple Myeloma (Kahler Disease). According...